News|Articles|March 13, 2024
Overcoming oncolytic virus therapy production challenges through collaboration
Author(s)ReciBioPharm
Discover how ReciBioPharm’s strategic approach helped to support the rapid delivery of an innovative oncolytic adenovirus therapy for advanced cancer to clinic.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
4
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
5
